Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nvx-cov2373 (Novavax)
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NVX-CoV2373 (Nuvaxovid) is a recombinant protein subunit nanoparticle vaccine developed by Novavax for the prevention of COVID-19. It consists of the full-length, prefusion-stabilized SARS-CoV-2 spike (S) protein (based on the Wuhan-Hu-1 strain) produced in a baculovirus/Sf9 insect cell expression system. The spike proteins are organized into nanoparticles and formulated with the proprietary saponin-based Matrix-M1 adjuvant. The vaccine works by inducing neutralizing antibodies and T-cell responses against the spike protein, which mediates viral entry into host cells via the ACE2 receptor. It has demonstrated high efficacy in Phase 3 clinical trials and is administered as a two-dose intramuscular regimen.
- Brand names
- NuvaxovidCovovax
- Other names
- SARS-CoV-2 recombinant spike protein nanoparticle vaccine + Matrix-M1 adjuvantNovavax COVID-19 vaccineSARS-CoV-2 rSSARS-CoV2 rSSARS-CoV 2 rSMatrix-M1 adjuvanted COVID-19 vaccineMatrix-M-1 adjuvanted COVID-19 vaccineMatrix-M 1 adjuvanted COVID-19 vaccine
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on nvx-cov2373 (Novavax).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nvx-cov2373 (Novavax).